Австралия - английский - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paracetamol, quantity: 665 mg - tablet, modified release - excipient ingredients: macrogol 6000; colloidal anhydrous silica; magnesium stearate; titanium dioxide; microcrystalline cellulose; povidone; hypromellose; purified talc; maize starch; pregelatinised maize starch; sodium starch glycollate type a - effective for the relief of persistent pain associated with osteoarthritis and muscle aches and pains such as backache. gxp paracetamol xr 665 mg also provides effective, temporary relief of pain and discomfort associated with headache, tension headache, period pain, toothache and pain after dental procedures, and cold and flu. reduces fever.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - paracetamol, quantity: 665 mg - tablet, modified release - excipient ingredients: sodium starch glycollate type a; macrogol 6000; hypromellose; titanium dioxide; maize starch; magnesium stearate; colloidal anhydrous silica; povidone; pregelatinised maize starch; purified talc; microcrystalline cellulose - effective for the relief of persistent pain associated with osteoarthritis and muscle aches and pains such as backache. genpar paracetamol xr 665 mg also provides effective, temporary relief of pain and discomfort associated with headache, tension headache, period pain, toothache and pain after dental procedures, and cold and flu. reduces fever.

Бельгия - английский - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

air liquide santé international s.a. - xenon 100 % - medicinal gas, liquefied - xenon - xenon

Австралия - английский - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; purified water; methyl hydroxybenzoate; citric acid; glycerol; carmellose sodium; sorbitol solution (70 per cent) (crystallising); sucralose; flavour - briviact oral solution is indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Австралия - английский - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: acesulfame potassium; purified water; maltitol solution; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; propyl hydroxybenzoate; sodium citrate dihydrate; glycerol; flavour - keppra (film coated tablets and oral solution) is indicated for - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation, - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. - add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and - add on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige). keppra concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paracetamol, quantity: 450 mg; codeine phosphate hemihydrate, quantity: 30 mg; doxylamine succinate, quantity: 5 mg - tablet, uncoated - excipient ingredients: purified talc; microcrystalline cellulose; magnesium stearate; sodium starch glycollate; hypromellose - mevadol forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: glycerol; purified water; sodium hydroxide; sorbitol solution (70 per cent) (non-crystallising); methyl hydroxybenzoate; ethanol; propyl hydroxybenzoate; sunset yellow fcf; quinoline yellow; flavour - oedema: lasix is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. lasix is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. lasix injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, lasix is indicated by the intravenous route. parenteral use should be replaced with oral lasix as soon as practical.hypertension. oral lasix may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with lasix alone.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nevirapine hemihydrate, quantity: 10.35 mg/ml (equivalent: nevirapine, qty 10 mg/ml) - oral liquid, suspension - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); propyl hydroxybenzoate; sodium hydroxide; carbomer 934p; polysorbate 80; sucrose; methyl hydroxybenzoate - viramune (nevirapine) oral suspension in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and children over the age of 2 months. viramune xr (nevirapine) extended-release tablets in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and children over the age of three years. extended-release tablets are not suitable for the 14 day lead-in period for patients starting nevirapine. other nevirapine formulations, such as immediate-release tablets or oral suspension should be used. resistant virus emerges rapidly when viramune is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, viramune should always be administered in combination with at least two additional antiretroviral agents.

Малайзия - английский - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

xepa-soul pattinson (malaysia) sdn bhd - paracetamol -

Малайзия - английский - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

xepa-soul pattinson (malaysia) sdn bhd - paracetamol -